Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
In late May 2025 a major funding round highlights how investors are backing clinical-stage pipelines together with AI …
Latest clinical updates highlight cutting-edge oncology treatments, AI advancements in drug development, and efforts to accelerate trial startup …
Big capital flows into companies marrying AI with cancer treatments suggest early-stage clinical research is shifting its centre …
New AI-powered system promises to reduce inefficiencies in trial recruitment by automating eligibility prediction
Leading biopharma companies are leveraging digital technologies and manufacturing expansions to enhance drug development and patient care.
Partnerships harnessing artificial intelligence are revolutionizing drug discovery, reducing timelines and improving candidate success rates.
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
Already a subscriber? Log in